Loading...

PE/Cyanine7 anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1dot5_PECy7_030206
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE/Cyanine7 (filled histogram) or rat IgG2b, κ PE/Cyanine7 isotype control (open histogram).
  • GK1dot5_PECy7_030206
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE/Cyanine7 (filled histogram) or rat IgG2b, κ PE/Cyanine7 isotype control (open histogram).
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
100421 25 µg 71€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100422 100 µg 172€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Sanmarco LM, et al. 2022. Nature. 611:801. PubMed
  2. Wang X, et al. 2023. J Immunother Cancer. 11:. PubMed
  3. Rege SV, et al. 2023. Commun Biol. 6:292. PubMed
  4. Saha S, et al. 2023. Sci Rep. 13:4609. PubMed
  5. del Rio ML, et al. 2023. Front Immunol. 14:1113858. PubMed
  6. Tang M, et al. 2023. Sci Adv. 9:eade6624. PubMed
  7. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
  8. Collin R, et al. 2020. J Immunol. 205:133. PubMed
  9. Alam A, et al. 2022. Cancer Cell. 40:153. PubMed
  10. Xiong T, et al. 2022. Cancer Sci. 113:1955. PubMed
  11. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  12. Zhao Z, et al. 2022. Adv Sci (Weinh). 9:e2201293. PubMed
  13. del Rio ML, et al. 2022. Front Immunol. 13:887348. PubMed
  14. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  15. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  16. Mansouri S, et al. 2022. J Immunol. 209:2114. PubMed
  17. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  18. Roy S, et al. 2022. Am J Cancer Res. 12:4977. PubMed
  19. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  20. Kulkarni R, et al. 2023. Life Sci Alliance. 6: . PubMed
  21. Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed
  22. Zhao K, et al. 2023. Front Immunol. 14:1101769. PubMed
  23. Novaj A, et al. 2023. Int J Mol Sci. 24: . PubMed
  24. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  25. Kodali S, et al. 2022. J Immunol. 208:1085. PubMed
  26. Meacham CE, et al. 2022. Nat Cell Biol. 24:697. PubMed
  27. Gogoi H, et al. 2020. Front Immunol. 1.620833333. PubMed
  28. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  29. Perruzza L, et al. 2019. Sci Rep. 9:9315. PubMed
  30. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  31. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  32. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  33. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  34. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  35. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  36. Groza D, et al. 2018. Oncoimmunology. 7:e1424676. PubMed
  37. Proietti M, et al. 2019. Nat Commun. 10:250. PubMed
  38. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  39. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
  40. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  41. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  42. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  43. Fernandes RA, et al. 2020. eLife. 9:e58463.. PubMed
  44. Diao L, et al. 2022. iScience. 25:105511. PubMed
  45. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  46. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  47. Crespo ÂC, et al. 2020. Cell. 182(5):1125-1139. PubMed
  48. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  49. Haertel E, et al. 2018. Eur J Immunol. 48:1001. PubMed
  50. Bowers E, et al. 2018. Nat Med. 24:95. PubMed
  51. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  52. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  53. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  54. Kaufmann U et al. 2019. Cell metabolism. 29(5):1104-1118 . PubMed
  55. Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed
  56. Rolla S, et al. 2010. J Immunol. 184:6124. PubMed
  57. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
  58. Ma YV, et al. 2021. MAbs. 13:2003281. PubMed
  59. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  60. Haugh KA, et al. 2021. eLife. 0.416666666666667. PubMed
  61. Wang C, et al. 2021. Cell Stem Cell. . PubMed
  62. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  63. Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed
  64. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  65. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  66. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  67. An J, et al. 2022. iScience. 25:103570. PubMed
  68. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  69. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  70. Wang H, et al. 2019. Nat Commun. 10:1898. PubMed
  71. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  72. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  73. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  74. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
  75. Ohmichi Y, et al. 2011. J Exp Med . 208:1015. PubMed
  76. O'Brien S, Zhang M 2015. J Immunol. 195: 695-705. PubMed
  77. Wang W, et al. 2020. Immunity. 51(6):1102-1118.e7.. PubMed
  78. Pinho S, et al. 2022. Nat Cell Biol. 24:290. PubMed
  79. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  80. Brandi P, et al. 2022. Cell Rep. 38:110184. PubMed
  81. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
  82. Momin N, et al. 2022. Nat Commun. 13:109. PubMed
  83. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  84. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  85. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  86. Akhter N, et al. 2016. J Biol Chem. 291: 23672 - 23680. PubMed
  87. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  88. Lee P, et al. 2014. J Immunol. 192:178. PubMed
  89. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
  90. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  91. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
  92. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  93. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  94. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  95. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  96. Lim CX, et al. 2020. Cell Rep. 3793:30. PubMed
  97. Zhou G, et al. 2019. FASEB J. 33:11396. PubMed
  98. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  99. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  100. Dai R, et al. 2021. Front Immunol. 12:727046. PubMed
  101. Li C, et al. 2021. Cell Metabolism. 33(8):1610-1623.e5. PubMed
  102. Kondo M, et al. 2016. J Immunol. 196: 563 - 572. PubMed
  103. XS R, et al. 2015. Diabetes. 64 90. PubMed
  104. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  105. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  106. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
  107. Kitajima Y, et al. 2022. Cells. 11:. PubMed
  108. Busse DC, et al. 2020. J Virol. 94:00:00. PubMed
  109. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
  110. Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed
  111. Zhou J, et al. 2022. Int J Oncol. 61: . PubMed
  112. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  113. Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed
  114. Godwin MS, et al. 2019. JCI Insight. 4:e126070. PubMed
  115. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  116. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
  117. Schönberger K, et al. 2022. STAR Protoc. 3:101408. PubMed
  118. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  119. Kojima H, et al. 2021. Scand J Immunol. 93:e13020. PubMed
  120. Wang W, et al. 2021. STAR Protocols. 2(3):100756. PubMed
  121. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  122. Draijer C, et al. 2018. Sci Rep. 8:5105. PubMed
  123. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  124. Li C, et al. 2018. Cell. 174:285. PubMed
  125. Nakornpakdee Y, et al. 2018. Asian Pac J Allergy Immunol. 36:265. PubMed
  126. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
  127. Godwin MS, et al. 2021. Am J Physiol Lung Cell Mol Physiol. 320:L393. PubMed
  128. Sanders K, et al. 2015. Cancer Immunol Res. 3: 891-901. PubMed
  129. Chen M, et al. 2019. Cell Stem Cell. 25:501. PubMed
  130. Kimura S, et al. 2020. Am J Transplant. 20:977. PubMed
  131. Kelley WJ, et al. 2022. JCI Insight. 7: . PubMed
  132. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  133. Prüss H, et al. 2017. Nat Neurosci. 10.1038/nn.4643. PubMed
  134. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
  135. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  136. Ambrosino E, et al. 2006. Cancer Res . 66:7734. PubMed
  137. Nagamata S, et al. 2019. Sci Rep. 9:3911. PubMed
  138. Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed
  139. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  140. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  141. Simula L, et al. 2022. Mol Oncol. 16:188. PubMed
  142. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
  143. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  144. Lerbs T, et al. 2020. JCI Insight. 5:00. PubMed
  145. Le TM et al. 2018. Journal of neurochemistry. 145(2):139-153 . PubMed
  146. Sadtler K, et al. 2017. Tissue Eng Part A. 23:1044. PubMed
  147. Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed
  148. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  149. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  150. Yu Z, et al. 2021. Biomed Res Int. 2021:9958745. PubMed
  151. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
  152. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  153. Groves HT, et al. 2020. MBio. 11:e03236-19. PubMed
RRID
AB_312706 (BioLegend Cat. No. 100421)
AB_312706 (BioLegend Cat. No. 100422)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD4
Specificity Alt (DOES NOT SHOW ON TDS):
CD4
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Spark PLUS UV395™ anti-mouse CD4 GK1.5 FC
Spark Red™ 718 anti-mouse CD4 (Flexi-Fluor™) GK1.5 FC
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account